Abraxane extends life of pancreatic cancer patients

Celgene’s Abraxane, in combination with chemotherapy, helped patients with advanced pancreatic cancer live about two months longer than those given chemotherapy alone, a study found.

Patients taking Abraxane with the chemotherapy gemcitabine survived a median of 8.5 months, compared with 6.7 months for those only on the single drug, Summit, N.J.-based Celgene said Tuesday in a statement. Based on the results, the company said it plans to file in the first half of the year for approval in the United States and Europe.

Pancreatic cancer killed an estimated 37,390 people in the U.S. last year, according to the National Cancer Institute. The disease spreads quickly and usually isn’t detected until it has advanced, making it a leading cause of cancer deaths, the Mayo Clinic says. Abraxane may generate $2.1 billion in peak global sales for use in pancreatic cancer, Eric Schmidt, an analyst with Cowen &Co., estimated.

“The past few decades have brought us very few treatment advances for patients with advanced pancreatic cancer, which is both deadly and incredibly difficult to treat with success,” Daniel Von Hoff, lead investigator of the trial and chief scientific officer for Scottsdale Healthcare’s Virginia G. Piper Cancer Center Clinical Trials, said in a statement. “The fact that Abraxane plus gemcitabine demonstrated an overall survival benefit, and also did so at one and two years, is a significant step forward in offering potential new hope for our patients.”

The 861-person study, from the third and final phase of clinical trials generally required for U.S. regulatory approval, showed that Abraxane helped more patients survive to one year, at 35 percent versus 22 percent in the gemcitabine-alone group. Nine percent of patients taking Abraxane survived to two years, compared with 4 percent receiving only gemcitabine.

Abraxane is a form of the chemotherapy paclitaxel that’s formulated with the human protein albumin to help deliver a strong dose directly to the tumor. Celgene acquired the drug in its 2010 purchase of Abraxis BioScience for $2.9 billion. It is approved to treat breast cancer and non-small cell lung cancer and generated sales of about $386 million in 2011.

The drug was related to a higher incidence of neutropenia, or low white blood cell count, at 38 percent compared with 27 percent. More patients also experienced fatigue, at 17 percent versus 7 percent, and neuropathy, or nerve damage, at 17 percent versus 1 percent. Gemcitabine is sold by Eli Lilly &Co. as Gemzar.

Analysts had been expecting a benefit in survival of at least two months, Michael Yee, of RBC Capital Markets, wrote in a Jan. 21 research note. Yee, who recommends buying Celgene shares, also said he was looking to see safety and tolerability in the Abraxane and gemcitabine regimen, noting another combination therapy, folfirinox, has much higher toxicity than gemcitabine, limiting its use despite an improvement in survival. The treatment combines chemotherapy drugs leucovorin, fluorouracil, irinotecan and oxaliplatin.

The data will be presented later this week at the American Society of Clinical Oncology’s 2013 Gastrointestinal Cancers Symposium in San Francisco.

More in Local News

‘Come talk to me. Don’t jump, come talk to me’

State Patrol trooper Yaroslav Holodkov just happened to be driving by when he saw a suicidal man.

Marysville educators reach out to a newly traumatized school

Several affected by shootings in 2014 offered to talk with counterparts in Eastern Washington.

Hurry! Target will take your old car seat, but not for long

The seats will be taken apart and the various materials recycled.

Sheriff’s Office receives national recognition

Sheriff accepts award “notable achievements in the field of highway safety” over the past year.

Edmonds-Woodway High School briefly locked down

A student tried to stop a fight and a boy, 16, responded by threatening the student with a knife.

Study considers making it legal to grow marijuana at home

The Liquor and Cannabis Board is considering two scenarios for allowing a minimal number of plants.

Minutes mattered the day Pat Ward was brought back to life

The Mukilteo police and fire chaplain died at breakfast. She got a second chance thanks to a waitress.

Whether cheers or jeers, DeVos appearance will rouse spirits

Trump’s secretary of education is coming to Bellevue to raise money for a pro-business think tank.

Woman fatally shot at home near Everett

Another woman and three children, who were also in the home, were not injured.

Most Read